Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
15.60
+0.16 (1.04%)
At close: Oct 3, 2025, 4:00 PM EDT
15.65
+0.05 (0.32%)
After-hours: Oct 3, 2025, 7:49 PM EDT
Syndax Pharmaceuticals Revenue
Syndax Pharmaceuticals had revenue of $37.96M in the quarter ending June 30, 2025, with 984.51% growth. This brings the company's revenue in the last twelve months to $77.93M, up 2,126.66% year-over-year. In the year 2024, Syndax Pharmaceuticals had annual revenue of $23.68M.
Revenue (ttm)
$77.93M
Revenue Growth
+2,126.66%
P/S Ratio
17.24
Revenue / Employee
$288,641
Employees
270
Market Cap
1.34B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 23.68M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | 139.71M | 138.19M | 9,109.56% |
Dec 31, 2020 | 1.52M | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SNDX News
- 2 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - 3 Potential Biotech Acquisition Targets - Seeking Alpha
- 16 days ago - Syndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia - GlobeNewsWire
- 25 days ago - Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC - Seeking Alpha
- 4 weeks ago - Syndax Pharmaceuticals, Inc. (SNDX) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 5 weeks ago - Syndax Announces Participation in September Investor Conferences - GlobeNewsWire
- 7 weeks ago - Syndax Pharmaceuticals: A Tale Of Two Drug Launches - Seeking Alpha
- 2 months ago - Syndax Pharmaceuticals: The Story Brightens - Seeking Alpha